ID29609A - Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol - Google Patents

Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Info

Publication number
ID29609A
ID29609A IDW20010189D ID20010189D ID29609A ID 29609 A ID29609 A ID 29609A ID W20010189 D IDW20010189 D ID W20010189D ID 20010189 D ID20010189 D ID 20010189D ID 29609 A ID29609 A ID 29609A
Authority
ID
Indonesia
Prior art keywords
durunan
tetrahidrofuran
purin
diol
Prior art date
Application number
IDW20010189D
Other languages
English (en)
Indonesian (id)
Inventor
David George Allen
Chuen Chan
Richard Peter Charles Cousins
Brian Cox
Joanna Victoria Geden
Heather Hobbs
Suzanne Elaine Keeling
Alison Judith Redgrave
Thomas Davis Roper Iv
Shiping Xie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813538.7A external-priority patent/GB9813538D0/en
Priority claimed from GBGB9909482.3A external-priority patent/GB9909482D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID29609A publication Critical patent/ID29609A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW20010189D 1998-06-23 1999-06-23 Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol ID29609A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9813538.7A GB9813538D0 (en) 1998-06-23 1998-06-23 Chemical compounds
GBGB9909482.3A GB9909482D0 (en) 1999-04-23 1999-04-23 2-(Purin-9-yl)-tetahydrofuran-3,4-diol derivatives

Publications (1)

Publication Number Publication Date
ID29609A true ID29609A (id) 2001-09-06

Family

ID=26313917

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010189D ID29609A (id) 1998-06-23 1999-06-23 Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Country Status (27)

Country Link
US (1) US6495528B1 (sh)
EP (1) EP1090022B1 (sh)
JP (1) JP3933870B2 (sh)
KR (1) KR20010071591A (sh)
CN (1) CN1313861A (sh)
AP (1) AP2000002016A0 (sh)
AT (1) ATE246701T1 (sh)
AU (1) AU750462B2 (sh)
BR (1) BR9911482A (sh)
CA (1) CA2335809A1 (sh)
CZ (1) CZ20004868A3 (sh)
DE (1) DE69910213T2 (sh)
EA (1) EA200001224A1 (sh)
EE (1) EE200000768A (sh)
ES (1) ES2204139T3 (sh)
HR (1) HRP20000894A2 (sh)
HU (1) HUP0103025A3 (sh)
ID (1) ID29609A (sh)
IL (1) IL140396A0 (sh)
IS (1) IS5779A (sh)
NO (1) NO20006548L (sh)
NZ (1) NZ509030A (sh)
PL (1) PL345062A1 (sh)
SK (1) SK19542000A3 (sh)
TR (1) TR200100410T2 (sh)
WO (1) WO1999067265A1 (sh)
YU (1) YU81100A (sh)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) * 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
KR20070058022A (ko) * 2000-04-26 2007-06-07 에자이 알앤드디 매니지먼트 가부시키가이샤 배변을 촉진하는 의약 조성물
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1778712B1 (en) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
WO2006023272A1 (en) 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0505219D0 (en) * 2005-03-14 2005-04-20 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
GB0523845D0 (en) * 2005-11-23 2006-01-04 Glaxo Group Ltd Novel salts
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607950D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
CN106632572B (zh) * 2016-12-16 2018-08-14 中国科学院成都生物研究所 一种黄芪甲苷衍生物及其制备方法和应用
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (en) 1972-04-10 1980-07-29 Francis E. Fischer Process for preparing adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
DE2621470A1 (de) 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
JPS58167599A (ja) 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
JPS58174322A (ja) 1982-04-07 1983-10-13 Tanabe Seiyaku Co Ltd 線溶促進剤
CA1239397A (en) 1983-08-01 1988-07-19 James A. Bristol N.sup.6-substituted adenosines
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
EP0300144A3 (en) 1984-04-18 1989-09-27 Whitby Research Incorporated N-6 alkyl substituted adenosine derivatives as cardiac vasodilators
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003147A1 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
WO1988003148A2 (en) 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
HU198950B (en) 1986-12-15 1989-12-28 Sandoz Ag Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
FI880405A (fi) 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
KR910007655A (ko) 1989-10-03 1991-05-30 엠. 피. 잭슨 치료용 뉴클레오시드
EP0423777A3 (en) 1989-10-19 1991-09-25 G.D. Searle & Co. Method of treating gastrointestinal motility disorders
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
ES2095960T3 (es) 1990-09-25 1997-03-01 Rhone Poulenc Rorer Int Compuestos que tienen propiedades antihipertensivas y antiisquemicas.
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (en) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sulfo-derivatives of adenosine
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
AU3255097A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
WO1998016539A1 (en) 1996-10-14 1998-04-23 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ZA9810766B (en) 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
YU44900A (sh) * 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol

Also Published As

Publication number Publication date
HUP0103025A3 (en) 2002-04-29
DE69910213D1 (de) 2003-09-11
AP2000002016A0 (en) 2000-12-31
CA2335809A1 (en) 1999-12-29
EP1090022B1 (en) 2003-08-06
IL140396A0 (en) 2002-02-10
ATE246701T1 (de) 2003-08-15
EP1090022A1 (en) 2001-04-11
CZ20004868A3 (cs) 2001-08-15
JP2002518512A (ja) 2002-06-25
EE200000768A (et) 2002-04-15
JP3933870B2 (ja) 2007-06-20
NO20006548D0 (no) 2000-12-21
BR9911482A (pt) 2002-01-22
US6495528B1 (en) 2002-12-17
EA200001224A1 (ru) 2001-08-27
NO20006548L (no) 2001-02-22
IS5779A (is) 2000-12-19
KR20010071591A (ko) 2001-07-28
PL345062A1 (en) 2001-11-19
SK19542000A3 (sk) 2001-09-11
DE69910213T2 (de) 2004-07-01
YU81100A (sh) 2003-10-31
AU750462B2 (en) 2002-07-18
WO1999067265A1 (en) 1999-12-29
HUP0103025A2 (hu) 2001-12-28
NZ509030A (en) 2003-07-25
HRP20000894A2 (en) 2001-12-31
ES2204139T3 (es) 2004-04-16
TR200100410T2 (tr) 2001-06-21
CN1313861A (zh) 2001-09-19
AU4774499A (en) 2000-01-10

Similar Documents

Publication Publication Date Title
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
ID22271A (id) Turunan-turunan 2-(purin-9-il) tetrahidrofuran-3,4-diol
MA26601A1 (fr) Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol .
ID29241A (id) Turunan-turunan kinolin teranelasi-1,2
FI980427A0 (fi) Foerfarande, arrangemang och anordning foer verifiering
CU23049A3 (es) Dihidropirimidinas.
ID23287A (id) Trisiklik tersubstitusi
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
ID28483A (id) 2-(3,5-bis-trifluorometil-fenil)-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il)-isobutiramida
ID23219A (id) Trisiklik tersubstitusi
ID26909A (id) Turunan-turunan 1,3,4-oksadiazolon
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
ATE234839T1 (de) 4,5-azolo-oxindole
ID27686A (id) Turunan 3-(2-okso-[1,3]bipirolidinil-3-ildenametil)-sefem
DE59912532D1 (de) Substituierte acylaminophenyl-uracile
DE59912188D1 (de) Substituierte phenyluracile
DE59911610D1 (de) Substituierte benzoylcyclohexandione
ID26368A (id) Turunan-turunan 2 deoksi higromisin
DE59909590D1 (de) Azidfreie, gaserzeugende zusammensetzung
ES1040916Y (es) Microterminal perfeccionado.
ES1039265Y (es) Rocodromo perfeccionado.
ES1039438Y (es) Expositor-expendedor perfeccionado.
FI980638A0 (fi) Foerfarande, arrangemang och anordning foer telekommunikation
ES1039413Y (es) Nueva ficha-deportista.